Open AccessContract Research Organization (CRO): An Important Partner to Biotechnological and Pharmaceutical Companies
Author(s) -
R. Santosh Kumar,
Sangbit Paul
Publication year - 2019
Publication title -
journal of drug delivery and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2250-1177
DOI - 10.22270/jddt.v9i4-a.3481
Subject(s) - profit margin , business , pharmaceutical industry , china , research development , margin (machine learning) , drug development , industrial organization , marketing , microbiology and biotechnology , drug , pharmacology , medicine , political science , computer science , law , paleontology , test (biology) , machine learning , biology
With the ever increasing Research and Development cost for the pharmaceutical industries, the cost of bringing a drug to market was increasing drastically. The funds for drug development was drying up and thus to maintain a healthy profit margin , the pharmaceutical companies have adopted to frame out research and development (R&D) to Contract Research Organizations (CRO’s). The CRO’s have become an important partner to biotechnological and pharmaceutical companies, in the development of new compounds and at the same time in drug registration also it has extended its hands. Out of 20, 19 pharmaceutical companies have invested in emerging markets like China, India, Russia and Latin America since clinical research is accessible to these markets due to adoption of ICH and GCPs guidelines. The traditional nature of CRO’s have changed and they will develop into a formidable industry in near future.